HUE059838T2 - Seladelpar primer epe cholangitis kezelésére - Google Patents

Seladelpar primer epe cholangitis kezelésére

Info

Publication number
HUE059838T2
HUE059838T2 HUE17722943A HUE17722943A HUE059838T2 HU E059838 T2 HUE059838 T2 HU E059838T2 HU E17722943 A HUE17722943 A HU E17722943A HU E17722943 A HUE17722943 A HU E17722943A HU E059838 T2 HUE059838 T2 HU E059838T2
Authority
HU
Hungary
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
HUE17722943A
Other languages
English (en)
Hungarian (hu)
Inventor
Pol Boudes
Charles Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of HUE059838T2 publication Critical patent/HUE059838T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17722943A 2016-05-31 2017-04-26 Seladelpar primer epe cholangitis kezelésére HUE059838T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
HUE059838T2 true HUE059838T2 (hu) 2023-01-28

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17722943A HUE059838T2 (hu) 2016-05-31 2017-04-26 Seladelpar primer epe cholangitis kezelésére

Country Status (27)

Country Link
US (5) US10272058B2 (https=)
EP (1) EP3463328B1 (https=)
JP (1) JP7079735B2 (https=)
KR (1) KR102408288B1 (https=)
CN (2) CN109195594A (https=)
AU (1) AU2017274293B2 (https=)
BR (1) BR112018074147A2 (https=)
CA (1) CA3024155C (https=)
CY (1) CY1125465T1 (https=)
DK (1) DK3463328T3 (https=)
ES (1) ES2921230T3 (https=)
HR (1) HRP20220903T1 (https=)
HU (1) HUE059838T2 (https=)
IL (1) IL263372B2 (https=)
LT (1) LT3463328T (https=)
MX (1) MX390417B (https=)
NZ (1) NZ748721A (https=)
PL (1) PL3463328T3 (https=)
PT (1) PT3463328T (https=)
RS (1) RS63345B1 (https=)
RU (1) RU2765460C2 (https=)
SG (1) SG11201810123SA (https=)
SI (1) SI3463328T1 (https=)
SM (1) SMT202200471T1 (https=)
UA (1) UA122719C2 (https=)
WO (1) WO2017209865A1 (https=)
ZA (1) ZA201808360B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2020102337A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash
FI4225291T3 (fi) * 2021-02-01 2024-06-03 Cymabay Therapeutics Inc Kolangiopatioiden hoito seladelpaarilla
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
PT3119384T (pt) 2014-03-20 2018-12-12 Cymabay Therapeutics Inc Tratamento de doenças colestáticas intra-hepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
EA201790091A1 (ru) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SMT202200171T1 (it) 2017-09-26 2022-05-12 Cymabay Therapeutics Inc Trattamento del prurito colestatico con seladelpar
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
WO2020102337A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
US20200061006A1 (en) 2020-02-27
BR112018074147A2 (pt) 2019-03-06
US10272058B2 (en) 2019-04-30
KR20190015363A (ko) 2019-02-13
EP3463328B1 (en) 2022-06-15
DK3463328T3 (da) 2022-07-04
CA3024155A1 (en) 2017-12-07
SI3463328T1 (sl) 2022-08-31
RU2018146504A3 (https=) 2020-07-27
MX2018014915A (es) 2019-04-24
KR102408288B1 (ko) 2022-06-10
IL263372A (en) 2018-12-31
JP7079735B2 (ja) 2022-06-02
US20210220305A1 (en) 2021-07-22
RS63345B1 (sr) 2022-07-29
AU2017274293B2 (en) 2022-03-31
US10478411B2 (en) 2019-11-19
RU2765460C2 (ru) 2022-01-31
WO2017209865A1 (en) 2017-12-07
CA3024155C (en) 2023-10-10
LT3463328T (lt) 2022-08-10
PT3463328T (pt) 2022-07-07
MX390417B (es) 2025-03-20
RU2018146504A (ru) 2020-07-09
SG11201810123SA (en) 2018-12-28
NZ748721A (en) 2022-04-29
SMT202200471T1 (it) 2023-01-13
CN109195594A (zh) 2019-01-11
AU2017274293A1 (en) 2018-12-13
PL3463328T3 (pl) 2022-10-03
JP2019518022A (ja) 2019-06-27
US20190255004A1 (en) 2019-08-22
ZA201808360B (en) 2020-02-26
US11000494B2 (en) 2021-05-11
CY1125465T1 (el) 2025-05-09
US20170340589A1 (en) 2017-11-30
US20210000774A1 (en) 2021-01-07
CN121466055A (zh) 2026-02-06
US11596614B2 (en) 2023-03-07
IL263372B2 (en) 2023-06-01
ES2921230T3 (es) 2022-08-22
EP3463328A1 (en) 2019-04-10
UA122719C2 (uk) 2020-12-28
US10813895B2 (en) 2020-10-27
HRP20220903T1 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
CY2025027I1 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειiτιδας
IL275482A (en) Asketamine for the treatment of depression
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
IL264143B (en) Processes for preparing olaparib
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
FI4327866T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitoon
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
ZA201903649B (en) Treatment for primary biliary cholangitis
DK3488443T3 (da) Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning
HUE059838T2 (hu) Seladelpar primer epe cholangitis kezelésére
BR112016022976A2 (pt) Métodos para o tratamento de hcv
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3377094T3 (da) Virulenssvækkede bakterier til behandling af ondartede solide tumorer
HUE064604T2 (hu) Menotropin meddõség kezelésére
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
CY2024037I1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
HUE042043T2 (hu) Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
DK3484475T3 (da) 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom